Associated Papers
MEK inhibitor Mirdametinib promotes fracture healing in osteofibrous dysplasia RASopathy.
Khalid A et al.
The Journal of Clinical Investigation, 2026
MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies.
Park J et al.
Targeted Oncology, 2025
Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report.
Umeda Y et al.
Thoracic Cancer, 2025
Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report.
Wilgucki M et al.
Jto Clinical and Research Reports, 2022
Case Report: A 91-Year-Old Patient With Non-Small Cell Lung Cancer Harboring MET Y1003S Point Mutation.
Gao B et al.
Frontiers in Medicine, 2021
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers.
Yang H et al.
Lung Cancer (amsterdam, Netherlands), 2020
MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Guo R et al.
Nature Reviews. Clinical Oncology, 2020
MET Y1003S point mutation shows sensitivity to crizotinib in a patient with lung adenocarcinoma.
Miao YL et al.
Lung Cancer (amsterdam, Netherlands), 2019
Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia.
Gray MJ et al.
American Journal of Human Genetics, 2015
Select a paper to view details